4.6 Review

Adaptive immunity programmes in breast cancer

期刊

IMMUNOLOGY
卷 150, 期 1, 页码 25-34

出版社

WILEY
DOI: 10.1111/imm.12664

关键词

adaptive immunity; breast cancer; immunotherapy; neoantigens; T cells

资金

  1. American Cancer Society [IRG-82-003-30]
  2. National Center For Advancing Translational Sciences of the National Institutes of Health [UL1TR001086]
  3. National Institute of General Medical Sciences of the National Institutes of Health [T32GM008704]
  4. Geisel School of Medicine at Dartmouth College

向作者/读者索取更多资源

The role of the immune system in shaping cancer development and patient prognosis has recently become an area of intense focus in industry and academia. Harnessing the adaptive arm of the immune system for tumour eradication has shown great promise in a variety of tumour types. Differences between tissues, however, necessitate a greater understanding of the adaptive immunity programmes that are active within each tumour type. In breast cancer, adaptive immune programmes play diverse roles depending on the cellular infiltration found in each tumour. Cytotoxic T lymphocytes and T helper type 1 cells can induce tumour eradication, whereas regulatory T cells and T helper type 2 cells are known to be involved in tumour-promoting immunosuppressive responses. Complicating these matters, heterogeneous expression of hormone receptors and growth factors in different tumours leads to disparate, patient-specific adaptive immune responses. Despite this non-conformity in adaptive immune behaviours, encouraging basic and clinical results have been observed that suggest a role for immunotherapeutic approaches in breast cancer. Here, we review the literature pertaining to the adaptive immune response in breast cancer, summarize the primary findings relating to the breast tumour's biology, and discuss potential clinical immunotherapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据